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Background. The mechanism of Plasmodium falciparum resistance to quinine is not known. In vitro quanti-
tative trait loci mapping suggests involvement of a predicted P. falciparum sodium–hydrogen exchanger (pfnhe–1)
on chromosome 13.
Methods. We conducted prospective quinine efﬁcacy studies in 2 villages, Kollé and Faladié, Mali. Cases of
clinical malaria requiring intravenous therapy were treated with standard doses of quinine and followed for 28 days.
Treatment outcomes were classiﬁed using modiﬁed World Health Organization protocols. Molecular markers of
parasite polymorphisms were used to distinguish recrudescent parasites from new infections. The prevalence of
pfnhe–1 ms4760–1 among parasites before versus after quinine treatment was determined by direct sequencing.
Results. Overall, 163 patients were enrolled and successfully followed. Without molecular correction, the mean
adequate clinical and parasitological response (ACPR) was 50.3% (n = 163). After polymerase chain reaction correc-
tion to account for new infections, the corrected ACPR was 100%. The prevalence of ms4760–1 increased signiﬁ-
cantly, from 26.2% (n = 107) before quinine treatment to 46.3% (n = 54) after therapy (P = .01). In a control
sulfadoxine–pyrimethamine study, the prevalence of ms4760–1 was similar before and after treatment.
Conclusions. This study supports a role for pfnhe–1 in decreased susceptibility of P. falciparum to quinine in the
ﬁeld.
Keywords. Malaria; recurrence; antimalarials; Plasmodium falciparum; drug resistance; sodium–hydrogen
antiporter; microsatellite; Mali.
Control of uncomplicated cases of malaria has been
greatly impaired by development of resistance against
mainstay antimalarial agents [1, 2]. The ﬁrst–line anti-
malarial strategy is presently artemisinin combination
therapy. Quinine (QN) is used in many malaria-
endemic countries for the management of severe life–
threatening malaria and as rescue therapy for parasites
resistant to other antimalarial drugs. As a monother-
apy, QN is associated with signiﬁcant recrudescence
rates [3]. This may be because QN is a rapidly acting
drug with a relatively short elimination half–life [4, 5].
Failure of QN in malaria treatment has been long doc-
umented, particularly in South America [6, 7] and
Southeast Asia [8]. Although high–level resistance of
Plasmodium falciparum to QN is rare, in vivo and in
vitro decreases in parasite susceptibility have led to the
use of this drug in combination, particularly with the
antibiotics tetracycline or doxycycline [9–13].
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The mechanisms of decreased P. falciparum susceptibility to
QN are not clearly understood. Modulation of in vitro QN sen-
sitivity has been associated with single nucleotide polymor-
phisms in the pfcrt (chloroquine–resistance transporter) and
pfmdr1 (multidrug resistance 1) genes [14, 15]. Involvement of
additional genes also seems to be important, because the associ-
ation of pfcrt and pfmdr1 is not always observed [16]. This
reality of a complex phenotype is also supported by the frequent
efﬁcacy of QN against chloroquine-resistant parasites [17, 18].
The availability of a laboratory-derived genetic cross between
2 parasites of markedly different in vitro QN responses [19]
permitted a quantitative trait loci–based approach that identi-
ﬁed genomic regions contributing to the phenotypes [18].
Analysis showed a possible association between reduced
P. falciparum susceptibility to QN and a locus on chromosome
13. A pairwise effect was also detected between that chromo-
some 13 locus and an additional locus on chromosome 9. The
set of predicted genes on the chromosome 13 locus included a
homologue to the family of Na+/H+ exchanger (NHE) pro-
teins [18]. The P. falciparum–encoded PfNHE–1 is 1920
amino acids long and harbors an open reading frame with a
microsatellite polymorphism consisting of variable DNNND
repeat units, designated ms4760. The predicted pfnhe–1 se-
quence was analyzed in the Dd2 × HB3 progeny, as well as in
a range of ﬁeld isolates and laboratory strains with variable sus-
ceptibilities to QN. Eight variants of ms4760 were originally dis-
covered. The variant ms4760–1 with 2 copies of DNNND repeat
units was signiﬁcantly associated with reduced in vitro QN sensi-
tivity [18]. These results were later supported by transfection
experiments [20]. The aforementioned studies were performed
with in vitro cultured laboratory strains. However, these poly-
morphisms were also present in natural P. falciparum popula-
tions [21] and found to be associated with QN sensitivity among
ﬁeld isolates in in vitro assays [22–24].
Here we extend these studies to clinical settings by explor-
ing the in vivo impact of QN therapy on the prevalence of the
pfnhe–1 ms4760 and pfcrt polymorphisms in 2 Malian
villages.
METHODS
Study Design and Procedures
This QN efﬁcacy study was conducted in Kollé and Faladié,
Mali. Kollé (with approximately 2800 inhabitants) is a rural
village located 57 km south of Bamako, the capital city of
Mali. Faladié (with approximately 3000 inhabitants) is located
80 km northwest of Bamako. Malaria is endemic in both vil-
lages, with seasonal transmission occurring between July and
December.
Patients presenting with clinical malaria requiring intrave-
nous treatment were eligible for the study. The 28–day World
Health Organization (WHO) 2003 protocol for antimalarial
drug efﬁcacy was adapted to the QN regimen [25]. Patients
aged ≥6 months who presented with P. falciparum malaria at
a parasitemia of ≥500 000 trophozoites/μL or who had ≥1
clinical symptom of severe malaria (eg, coma [Blantyre coma
scale score of <2], prostration, inability to drink or eat, vomit-
ing, convulsion, obsessing, respiratory distress, icterus, and
hematuria associated with the presence of parasites) were in-
cluded. Informed consent or assent was obtained before any
protocol–speciﬁc procedure was performed. Pregnant women,
patients allergic to QN, and patients whom the physician be-
lieved to be too severely ill were excluded from the study. At
inclusion, thick and thin blood smears and full clinical exami-
nations were performed for each.
Patients enrolled during 2005–2007 were treated with 12.5
mg/kg QN twice daily for 5 days. In 2008, the regimen was
changed to 8 mg/kg 3 times daily for 7 days, according to
established protocols (WHO malaria treatment guideline 2006
[WHO/HTM/MAL/2006.1108]). All patients received full cu-
rative doses of QN, which was administered by the study team
in an inpatient setting. QN treatment was administered intra-
venously with 10% hypertonic glucose solution until the
patient was able to receive oral treatment.
Follow–up was adapted to the QN treatment schedule.
Brieﬂy, active follow–up was performed on days 1–7, 14, 21,
and 28. Body weight, height, axillary temperature, splenome-
galy prevalence, pulse rate, breathing rate, and other signs of a
severe condition were measured and recorded on case report
forms. For laboratory assessments at enrollment and at each
follow–up visit (days 0, 1, 3, 7, 14, 21, and 28 and during un-
scheduled visits), thick and thin blood ﬁlms and blotting of
blood onto ﬁlter paper samples were performed. Thick and
thin blood ﬁlms were stained with Giemsa stain, and parasite
density was determined by dividing the number of asexual
parasites by 300 leukocytes and multiplying by 7500 (the esti-
mated mean of leukocytes/microliter of blood) [26].
Treatment outcomes were deﬁned according to the clinical or
parasitologic response and were classiﬁed as early therapeutic
failure (ETF), late clinical failure (LCF), late parasitological failure
(LPF), and adequate clinical and parasitologic response (ACPR),
according to slight modiﬁcations of WHO protocols [25].
Cases of QN treatment failure were treated with artesunate–
amodiaquine or artemether–lumefantrine, according to the
Malian National Malaria Control Program guidelines. Severe
malaria cases that could not be managed in the ﬁeld clinic
were referred to teaching hospitals in Bamako.
As a control, a prospective sulfadoxine-pyrimethamine efﬁ-
cacy study was conducted as described elsewhere in Kollé
during 2007 and 2008 [27]. The prevalence of ms4760–1 in
baseline and post–sulfadoxine–pyrimethamine infections was
measured.
The study was approved by the Ethics Committee of the
Faculty of Medicine, Pharmacy, and Odonto–Stomatology,
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University of Bamako, Mali, and the Ethics Committee of the
National Institutes of Allergy and Infectious Diseases, Nation-
al Institutes of Health, Bethesda.
Molecular Methods
P. falciparum genomic DNA was extracted from blood blotted
onto ﬁlter paper samples by an established methanol–based
method [28].
Molecular markers of parasite polymorphisms pfmsp1,
pfmsp2, and CA1 were used to distinguish recrudescent para-
sites from new infections by nested polymerase chain reaction
(PCR), as described elsewhere [29, 30]. A sample was classiﬁed
as a true failure if it was recrudescent with all 3 markers.
The diversity of ms4760 was determined by direct PCR am-
plicon sequencing in all samples before QN treatment and in
all recurrent parasitemia during the 28–day follow–up. Nested
PCR was performed for the ﬁrst PCR ampliﬁcation, with the
following primers and conditions: F1fw 5′–GACAATTTCGG-
TAGATGCCCTAT–3′ and R1rev 5′–GGTCTTGCAGTGCAT
GGA–3′, using 1 × buffer, 1.5 mM of MgCl2, 200 µm of each
dNTP, 1 µm of each primer, and 0.625 U of the Taq DNA po-
lymerase (Invitrogen, San Diego, CA, USA). The product was
used to perform the second ampliﬁcation with the following
primers, under the same conditions as the ﬁrst ampliﬁcation:
F2fw 5′–AGTGGTAGTAATAATGATA–3′ and R5rev 5′–GTA
CCCTTAGTTGAAATATT–3′. Products of approximately
350 base pairs from the second ampliﬁcation were treated
with ExoSAP–IT enzyme, as recommended by the manufac-
turer (USB, Cleveland, OH). The obtained product was capil-
lary sequenced using the second ampliﬁcation primers F2fw
and R5rev and ﬂuorescent nucleotides in an ABI 3730XL au-
tomatic sequencer (Applied Biosystems, Foster City, CA). The
prevalence of ms4760–1 among parasites before versus after
QN treatment was determined. Conversely, as a negative
control, we measured the prevalence of ms4760–1 at baseline
and after sulfadoxine–pyrimethamine treatment. DNA was ex-
tracted from blood blotted ﬁlter papers that was collected
before treatment and for any parasitemia after administration
of sulfadoxine–pyrimethamine. Sequencing was performed as
described above. The polymorphism of pfnhe–1 ms4760 was
determined by alignment. The prevalence of pfnhe–1 ms4760
was compared between the pretreatment and posttreatment
infections.
Samples collected before and after QN treatment and for
which the results from pfnhe–1 analyses were available were
tested for the pfcrt K76T codon, using previously described
methods [31].
Quinine Plasma Levels
Plasma QN levels were determined in blood samples collect-
ed at 3 time points: before QN administration on day 0, 7
days after the initiation of treatment, and 14 days after the
initiation of treatment. Only patients with samples from the 3
time points described above were included in this pharmaco-
kinetic analysis. Fifty microliters of plasma were used for QN
quantiﬁcation. Quinine was measured by liquid chromato-
graphy with spectrometric detection after extraction by a di-
chloromethane isopropanol mixture in the presence of
hydroquinidine chlorhydrate as an internal standard. Detec-
tion was by excitation at 350 nm and ﬂuorometric emission at
440 nm, using a ﬂow rate of 2 mL/min, with the injection rate
set at 30 µL. A 4.6 mm × 25 cm ultrasphere column with octa-
decylsilane particles (Beckman) was used (the protocol was
developed at Laboratoire de Pharmacologie Analytique et
Pharmacocinétique, Hôpital Saint–Vincent de Paul, Paris
France).
Data Analysis
Patients were included in the analysis only if they received the
correct dose of the study drug, attended all follow–up visits,
and did not take another antimalarial drug during the follow–
up period.
EpiInfo version 6.04 (Centers for Disease Control and Pre-
vention, Atlanta, GA), SPSS 11.0 (The Predictive Analytics;
IBM, Chicago, IL), and STATA 9.1 (StataCorp, College
Station, TX) were used to generate summary statistics and to
compare therapeutic efﬁcacy. The Spearman correlation test
was used to assess the relation between ms4760–1 and the
pfcrt K76T codon mutation. The prevalence of polymorphisms
before versus after QN therapy was compared with the Fisher
exact test and 2 × 2 contingency table analysis. Sequencher vs
4.7 (Gene Codes, Ann Arbor, MI) was used to align and
compare ﬁeld sample sequences with the previously described
8 variants of pfnhe–1 ms4760 [18].
RESULTS
In Vivo Quinine Efﬁcacy
Overall, 169 patients were enrolled (83 from Faladié and 86
from Kollé). Six were lost to follow–up, yielding 163 patients
for the ﬁnal in vivo analyses. Without molecular correction,
the mean ACPR was 50.3% (Table 1). After PCR correction to
Table 1. In Vivo Quinine Efﬁcacy Among Subjects From Faladié
and Kollé, Before and After Molecular Correction
Parameter
Faladié, Subjects,
% (n = 82)
Kollé, Subjects,
% (n = 81)
Overall, Subjects,
% (n = 163)
LCF 12.4 23.5 17.9
LPF 39.5 23.5 31.5
ACPR 48.2 53.1 50.3
ACPRc 100 100 100
Abbreviations: ACPR, adequate clinical and parasitological response; ACPRc,
adequate clinical and parasitological response after molecular correction; LCF,
late clinical failure; LPF, late parasitological failure.
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account for new infections, the corrected ACPR was 100%
(Table 1). Results for the 2 villages were similar. Overall, 81
patients (49.7%) had a patent infection during follow–up.
After the 5–day and 7–day QN treatment regimens, 69 of 126
patients (54.8%) and 12 of 37 patients (32.4%), respectively,
presented with posttreatment parasitemia (P = .01). The 7–day
treatment regimen delayed reinfections by 5 days, from day 14
to day 19 after treatment initiation.
Most (94%) of the 163 patients cleared parasitemia by day 3
after initiation of QN therapy, while all patients had cleared
parasitemia and fever by day 7.
Molecular Analysis
All 163 day 0 samples were available for molecular analysis,
while only 73 of 81 posttreatment samples were available. Of
the 236 samples ampliﬁed by PCR, 22.9% were mixed infec-
tions and did not yield usable sequences. PCR and sequencing
were successful in 107 of 163 samples (65.6%) obtained before
QN therapy and in 54 of 73 (74.0%) obtained after QN
therapy. The polymorphism of pfnhe–1 ms4760 was deter-
mined by alignment and compared between pretreatment and
posttreatment samples.
Overall, 6 of the 8 pfnhe–1 microsatellites described by
Ferdig et al [18] and 10 other ms4760 variants were found.
Alignment of these variants showed new deletions or inser-
tions (Figure 1), of which 5 had been observed in other
studies with samples from Africa and India [24, 32–34].
ms4760–1 was present in 26.2% of samples (107) obtained
before QN treatment but in 46.3% of samples (54; P = .01) ob-
tained after QN treatment. The odds of recurrent parasitemia
after QN therapy among patient presenting with ms4760–1 at
day 0 were 2.4 times the odds among patients who did not
present with ms4760–1 at day 0 (95% conﬁdence interval,
1.2–4.8). In the control sulfadoxine–pyrimethamine study, the
prevalence of ms4760–1 before treatment was not statistically
different from the prevalence after treatment (Table 2).
There was a trend toward decreased prevalence of ms4760–
1 from day 14 (66%; n = 9) to later time points (days 21–28;
42.2%; n = 45). Interestingly, at each of these time points, the
prevalence of ms4760–1 remained higher than at baseline
(data not shown).
The ms4760-3 marker, in contrast, was signiﬁcantly more
prevalent before treatment (36.4%) than after treatment
(14.8%; P = .004). The remaining microsatellites were random-
ly distributed before and after the QN treatment (Table 3)
Among the samples from both villages, pfcrt codon 76 anal-
ysis was successful in 74 pre–QN and 28 post-QN treatment
samples. Mixed infections with both wild-type and mutant
alleles were excluded. The prevalence of the pfcrt 76T codon
was similar in the pretreatment samples, compared with the
posttreatment samples (Table 4)
Figure 1. Alignment of ms4760 microsatellite sequences from different Plasmodium falciparum lines. A, The 8 sequences described by Ferdig et al
[18]. B, The 10 new sequences from the Malian Quinine study. DNNND copies are highlighted in bold. Asterisks indicate base changes to the encoding
nucleotide sequence. Insertions are underlined. New sequences found in Mali are classiﬁed from ms4760-9 to ms4760-18.
Table 2. Selection of ms4760-1 by Quinine but Not Sulfadoxine-










% (No.) P a OR (95% CI)
Quinine 26.2 (107) 46.3 (54) .01 2.43 (1.2–4.8)
SP 31.8 (44) 14.3 (21) .23 0.36 (.09–1.4)
Abbreviations: CI, confidence interval; OR, odds ratio.
a By the χ2 or Fisher exact tests.
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Pharmacokinetics Analysis
Of 30 patients included in the PK study, a subset of 12 showed
interpretable results. Among those 12 patients, the mean plasma
level of QN was 25 µg/mL at day 7 (interquartile range, 1.88–
3.11) but was below the detection limit of 1 µg/mL at day 14.
DISCUSSION
In this study, QN treatment selected malaria parasites with the
pfnhe–1 microsatellite ms4760–1. The observed selection
appears to be QN speciﬁc, as the treatment with sulfadoxine–
pyrimethamine was not associated with such selection of
ms4760–1 in posttreatment parasites.
Our data are in agreement with the study by Ferdig et al [18]
that found an association between pfnhe–1 and decreased sus-
ceptibility to QN. They are also consistent with other studies
that assessed the role of pfnhe–1 in P. falciparum resistance to
QN in culture–adapted parasites [16, 33], culture–adapted
P. falciparum ﬁeld isolates, or ex vivo experiments [32]. More-
recent in vitro studies also point to the involvement of the
pfnhe–1 gene in modulation of QN response in vitro in ﬁeld
samples [33], and Nkruma et al [20] provide transfection data
that support a role for pfnhe–1 in QN resistance, albeit in a
strain–dependent manner. Finally, Ugandan ﬁeld isolates har-
boring ms4760–1 showed a modest decrease of in vitro QN
sensitivity, but the presence of ms4760–1 did not predict clini-
cal failure during the in vivo study [34]. Our results are,
however, at odds with other recent reports suggesting that the
pfnhe–1 ms4760 microsatellite was not associated with QN sus-
ceptibility in the Republic of Congo, in Asia [23, 35], and in
travelers returning to France from various countries [36]. These
discordant ﬁndings suggest that the role of pfnhe–1 in QN re-
sistance may be dependent on the genetic background of the
parasites [20] and/or geographic origin [23].
When markers of parasite polymorphisms were used to dis-
tinguish true recrudescent infections from reinfections, we
found that all recurrent parasites were different from the origi-
nal day 0 parasites. Yet, we show clinical evidence for signiﬁ-
cant selection of ms4760-1 on initiation of QN therapy.
Furthermore, given the low serum levels of QN on day 14—
consistent with its pharmacokinetic characteristics—the ques-
tion arises of how this selection of ms4760–1 would have
occurred in vivo. One hypothesis might be that the observed
selection was merely due to normal biological ﬂuctuations
during follow–up. However, in these same villages, when sul-
fadoxine–pyrimethamine was used to treat patients, there was
no selection of ms4760-1, indicating that the selection ob-
served in the QN study was indeed due to an effect of QN.
Most of the selective effect was observed in parasites ap-
pearing in the bloodstream at day 14. This peak of selection
just 2 weeks after initiation of treatment raises the possibility
that these parasites might have been released from the liver,
which could have occurred 6–10 days earlier [37] and then
could have been selected by residual low-level QN pressure. It
is also possible that the parasites that appeared at day 14 were
indeed present at day 0, although at levels undetectable even
by nested PCR. QN might have cleared the highly susceptible
parasites, while parasites with decreased susceptibility or, pos-
sibly, those that were metabolically quiescent could have re-
covered in numbers to become detectable at day 14 or beyond.
This is supported by our observation that, when QN was ad-
ministered for a longer period, the rate of recurrent parasite-
mia decreased and the time to patent parasitemia increased.
We note that no QN was detectable by HPLC at day 14. This
is consistent with results of mathematical models [38] and
Table 3. ms4760 Diversity Among Parasites in Samples Collected







Parasites (n = 54) P
ms4760-1 26.2 46.3 .01
ms4760-2 0 0 NA
ms4760-3 36.4 14.8 .004
ms4760-4 0 0 NA
ms4760-5 1.9 1.85 .5
ms4760-6 3.7 1.85 .8
ms4760-7 22.5 16.7 .3
ms4760-8 3.7 7.4 .5
ms4760-9 0 1.85 NA
ms4760-10 0 1.85 NA
ms4760-11 1.9 0 NA
ms4760-12 0 1.85 NA
ms4760-13 0 1.85 NA
ms4760-14 0.9 0 NA
ms4760-15 1.9 0 NA
ms4760-16 0 1.85 NA
ms4760-17 0.9 0 NA
ms4760-18 0 1.85 NA
The predominant variants are in bold.
Abbreviation: NA, not applicable.
Table 4. pfcrt K76T Proﬁle Distributions Among Parasites
Harboring ms4760–1 in Samples Collected Before and After





Samples, % (No.) P
pfcrt 76T 69.0 (74) 64.3 (28) .6
ms4760–1/
pfcrt 76T
55.6 (18) 80.0 (10) .3
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with our previous observations, in which pyrimethamine treat-
ment selected DHFR mutant parasites within weeks, although
these parasites were undetectable at day 0 [39], as well as with
studies performed in Malawi, where the pfcrt 76T codon was
not detected by conventional nested PCR but was detected in
25% of subjects by a heteroduplex tracking assay [40].
The observed efﬁcacy of QN (after molecular correction to
distinguish new infections) is consistent with several other
reports reviewed by Okombo et al [24]. However, overall,
49.7% of 163 patients had a patent infection during the 28–
day follow–up, which is comparable to the failure rate ob-
served in other studies, using a similar treatment dose of
30 mg/day in 3 doses for 5 days [4, 41]. The rate of reinfection
on day 14 justiﬁed the change of treatment duration from 5 to
7 days, which not only decreased the rate of recurrent parasi-
temia but also increased the time to patent parasitemia by
5 days. Thus, as previously shown, treatment duration is im-
portant in QN’s in vivo efﬁcacy [42].
We found that the uncorrected ACPR after QN treatment
was 50.3%. These parasites may represent new infections from
novel mosquito bites in these settings of intense malaria trans-
mission. As discussed above, these parasites may also be new
blood-stage organisms emerging from the liver. In either case,
the fact that half of the patients would be sent home with im-
pending parasitemia is of public health concern. This is consis-
tent with several previous reports and supports the current
recommendation of intravenous artesunate for the manage-
ment of severe malaria [43–45]. In areas where intravenous ar-
tesunate is not available, QN treatment should be followed
with a full course of an artemisinin combination therapy
before discharge from the hospital. Alternatively, a drug that
kills liver-stage parasites may be a good adjunct to QN therapy.
As shown in several other recent ﬁeld studies [17, 22, 24, 32,
34, 46], in addition to 6 of the 8 pfnhe–1 microsatellites de-
scribed by Ferdig et al [18], we discovered 10 novel microsatel-
lites randomly distributed before and after the QN treatment.
This conﬁrms the high diversity of P. falciparum in Malian set-
tings. ms4760-3 was the most represented microsatellite in our
samples before QN treatment, followed by ms4760-1 and
ms4760-7, whereas ms4760-2 and ms4760-4 were not found in
this study. Other types, including the new ones, were all in low
frequencies. This observation is similar to the East Africa
ms4760 proﬁle [18, 24, 34], while the Asian setting harbors
mainly ms4760-7 [18, 35]. This diversity in ms4760 in the 2 vil-
lages in Mali was not affected by QN treatment. The signiﬁcance
of the counterselection of ms4760–3 by QN treatment was not
known.
A few studies [14, 15, 21] have implicated pfcrt and/or an
interaction between pfcrt and ms4760–1 in the phenotype of
decreased susceptibility of P. falciparum to QN. We found no
selection of pfcrt by QN treatment in vivo, although a trend
for an increase in the ms4760–1 + pfcrt76T haplotype was
noted. This trend did not reach statistical signiﬁcance. The
role of “ms4760–1 + pfcrt 76T” in QN resistance in the ﬁeld
needs further investigation in larger studies.
Although QN treatment selected pfnhe–1 ms4760–1, one
might ask whether this microsatellite could be used as a mo-
lecular marker for QN resistance. We found that patients who
presented with ms4760–1 at day 0 were nearly 2–fold more
likely to have a recurring parasitemia after QN treatment, but
the conﬁdence interval was too wide for the association to
reach statistical signiﬁcance, probably because of the relatively
small sample size. This comparatively small scale of the study
was due to the logistic difﬁculties associated to the perfor-
mance of these types of in vivo ﬁeld studies. First, QN is only
indicated for severe malaria, which is an unusual event [45].
Second, because of the need for multiple samples, for ethical
reasons we could only include patients who were ill enough to
warrant QN treatment but not too severely ill to undergo the
study procedures. These difﬁculties are reﬂected in the fact
that it took approximately 4 years to include 169 suitable cases
in this study. Finally, to avoid alterations of the parasite popu-
lation by culture adaptation, we performed direct sequencing
of PCR products from blood samples collected directly from
the patients, and nearly 23% of the 236 samples indicated
mixed infections and did not yield usable sequences. Apart
from the obvious difﬁculties, our study warrants the future
conduct of similar but larger studies. Such studies are neces-
sary for conﬁrming the present observation and allow the
pooling of data (eg, in the context of the WWARN initiative)
for the full assessment of the role suggested here of ms4760–1
as a molecular marker of QN resistance.
In conclusion, our study is the ﬁrst to demonstrate the
selection of pfnhe–1 ms4760–1 by QN treatment in vivo and
supports an important role for this locus in QN resistance in
the ﬁeld.
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